The differences between the two groups. Was a trend for the differences in BMD changes Ver To post tumor cell injection site 10 weeks between the treatment groups 0.04g/day observed, pairwise comparisons made to avoid the L Runs out of time trends for BMS-582664 Brivanib alaninate significant effects. Pairwise comparisons were applied, both face-and p-values of 0.05 considered statistically significant. For studies on the efficacy of cancer, were included from four to 10 animals per dose group for 21 days and treatment for end-stage data analysis. For the experiments with multiple myeloma, three contain up to 10 animals per dose group treatment for 10 weeks and in the final stage of data analysis. The number The results for MBC 11 were collected from three separate experiments.
RESULTS reps Possibility of MBC 11 to BALB / c and SCID Mice treated BALB / c had a maximum of 500 g / day MBC 11 is an average weight gain of 1 2 gw During the administration period of 24 days. M treated SCID Mice with up to 500 g / day MBC MBC is 11 or 29 years had an average weight gain of 2 f 3g During the dosing period of 49 days. These increases were in weight WZ3146 gain of M Mice treated with PBS. Renal function was generally within the normal range at M Mice with MBC MBC treated 11 or 29. Erg Complementary tables S4 and S5 show that mice Mice that were treated with 50 g / day MBC 1 and 9, a significant decrease in the K Rpergewichts and abnormal BUN and creatinine levels were compared to M, treated with PBS. Reinholz et al. Page 6 bone.
Author manuscript, increases available in PMC 2011 1 July. PA Author Manuscript NIH-PA Author Manuscript NIH Author Manuscript NIH PA Effects of MBC on 11 Bone tumor burden at M Mice with orthotopic mouse mammary cells and sacrificed 4T1/luc vaccinated 2A shows that 21-day-63% 100% of the Mice treated with PBS, AraC, etidronate, zoledronate were AraCetidronate and had bone metastases detected on Day 21 Fifty percent of the Mice, treated with MBC 29 and 47% of the 17 treated Mice had detectable bone MBC 11 days 21 metastases.at significant differences in the incidence of bone metastases were observed between the treatment groups PBS and 0.04 g / day. Mice treated with 0.04 g / day MBC 11 seemed to have a lower incidence of bone metastases by 40% are compared to those treated with PBS or 0.04 g / day zoledronate.
No significant difference in the H FREQUENCY of bone metastases were between PBS and 4.0 g / day treatment groups determined. 2B shows that the amount of luciferase activity t bone on day 21 significant difference between PBS and 0.04 g of treatment group / day. Wilcoxon tests showed that: different bones luciferase content did not differ significantly between M mice with PBS or 0.04 g / day ARAC, etidronate, etidronate AraC or zoledronate treated, and the luciferase content of bone was significantly lower in mice M with 0.04 g / day MBC 11 in PBS, and AraCetidronate M zoledronate-treated Mice treated. Was no significant difference between PBS and 4.0 g / day treatment groups was observed. Effects of MBC on 11 Sacrificed bone volume and architecture in M Mice on day 28, the final stage of bone volume in 15 Mice treated with zoledronate was controlled like Positive uses and was comparable to that observed in five healthy M Mice, not injected with the tumor cells. Bone volume was significantly different between the PBS and 0.04 g / day or 4.0 g / day treatment groups. Bone-B walls